[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fang Wu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100447943","the-effectiveness-and-safety-of-sbrt-in-the-treatment-of-patients-with-mplc-after-surgery-smile-100447943",false,"NCT05113017","The Effectiveness and Safety of SBRT in the Treatment of Patients With MPLC After Surgery (SMILE)","To Evaluate the Effectiveness and Safety of Stereotactic Radiotherapy (SBRT) in the Treatment of Patients With Residual Malignant Pulmonary Nodules After Lung Cancer Surgery: A Multi-center, Prospective Clinical Trial (SMILE)","SMILE","Inclusion Criteria:\n\n(1) Age 18-75 years old; (2) ECOG score 0-2 points; (3) Chest CT showed at least two lung nodules (pure ground glass, partial solid or solid nodules); (4) At least one lesion has been pathologically diagnosed as lung cancer (T1N0M0-T1N1M0); (5) At least one residual pulmonary nodule has been diagnosed pathologically or multidisciplinary diagnosis and treatment (MDT) discussed and considered as a primary malignant pulmonary nodule; (6) The residual lung nodules are inoperable or operable but the patient refuses to be surgically removed; (7) Have self-consciousness and can sign informed consent; (8) Must be able to swallow tablets.\n\nExclusion Criteria:\n\n(1) There are metastatic pulmonary nodules; (2) Have received chest radiotherapy in the past; (3) Lymph node metastasis or distant metastasis; (4) The tumor is located in the proximal bronchial tree area. The proximal bronchial tree is defined as carina, left and right main bronchus, left and right upper lobe bronchus, middle bronchus, right middle lobe bronchus, lingual bronchus, left and right lower lobe bronchi; the proximal bronchial tree area is defined as surrounding the proximal bronchial tree in all directions The area within 2cm above; (5) Pneumonectomy patients; (6) Severe primary diseases such as heart, liver, kidney, hematopoietic system, etc.; (7) Women during pregnancy and lactation; (8) Active period of the human immunodeficiency virus (HIV) infection; (9) Those with active systemic infection, pneumonia, tuberculosis, and pericarditis; (10) There is a history of psychotropic drug abuse or drug abuse;(11)Insulin dependent diabetes;(12) Thyroid disease","ALL","18 Years","75 Years",{"count":21,"type":22},40,"ESTIMATED","2 Years","OBSERVATIONAL","To prospectively evaluate the effectiveness and safety of SBRT in the treatment of residual malignant pulmonary nodules after lung cancer, and is committed to providing new treatment options for patients with multiple primary malignant pulmonary nodules who cannot tolerate multiple operations.",[27],"The Efficacy and Safety of SBRT in MPLC",[29],"SBRT, MPLC, Efficacy, Safety","RECRUITING","2025-11-21",{"date":33,"type":34},"2025-11-28","ACTUAL",{"date":36,"type":34},"2021-07-01",{"date":38,"type":22},"2026-12-31",{"name":40,"class":41},"Fang Wu","OTHER",5,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":24,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100454485","ctdna-analysis-to-monitor-the-risk-of-progression-after-first-line-immunotherapy-in-patients-with-advanced-nsclc-100454485","NCT05198154","ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC","A Multicenter, Prospective Clinical Study of Circulating Tumor DNA Analysis to Monitor the Risk of Progression After Long-term Benefit to First-line Immunotherapy in Patients With Advanced NSCLC (CR1STAL)","CR1STAL","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Advanced non-small cell lung cancer (stage IIIB-IV), pathological types limited to squamous cell carcinoma or non-squamous cell carcinoma, driver gene mutations (EGFR\u002FALK\u002FROS1) were negative\n* General condition: ECOG score 0 or 1\n* First-line monotherapy or combination immunotherapy\n* The long-term benefit of immunotherapy was defined as PFS=12months\n* Tumor tissue samples can be obtained at the time of enrollment, and at least 5 \\~ 10 sections can be generated, and the pathological report indicates that the overall tumor content is not less than 10% or NGS testing with a fixed-panel is available; or no tumor tissue is available.\n* At least one measurable lesion (except patients with CR after first-line treatment) can be evaluated according to RECIST1.1 standard.\n* Have self-awareness, be able to understand the research scheme and voluntarily participate in the study, and can sign the informed consent form\n* Have good compliance, be able to cooperate with the collection of specimens from each node and provide corresponding clinical information.\n\nExclusion Criteria:\n\n* Serious primary diseases of the heart, liver and kidney\n* Other malignant tumors within 3 years prior to diagnosis of NSCLC\n* Women in pregnancy and lactation\n* The active stage of human immunodeficiency virus (HIV) infection\n* Patients with active systemic infection, pneumonia, tuberculosis, pericarditis\n* Patients who cannot understand the content of the experiment and cannot cooperate and refuse to sign informed consent.",{"count":52,"type":22},100,"3 Years","This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)",[56],"Advanced Lung Non-Small Cell Carcinoma",[58,59,60,61,62,63],"ctDNA","advanced lung cancer","first-line immunotherapy","the risk of progression","minimal residual disease (MRD)","long-term benefit","2025-04-17",{"date":66,"type":34},"2025-04-23",{"date":68,"type":34},"2022-01-24",{"date":70,"type":22},"2025-12-30",{"name":40,"class":41},1,""]